All News
Unmasking Lupus Pregnancy: Adherence and Drug Monitoring Dilemmas
Risk of poor pregnancy outcomes in lupus patients continues to remain high, especially in the setting of high disease activity. Preliminary data from a lupus pregnancy LEGACY cohort presented at EULAR 2023 raise concern.
Read Article
Promising new therapies in SLE
Dr. Yuz Yusof ( @Yuz6Yusof ) weighs in.
The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians.
https://t.co/cdVw771HDs https://t.co/OYcN8hFLcP
Links:
Dr. John Cush RheumNow ( View Tweet)
Unmasking Lupus Pregnancy: Adherence and Drug Monitoring Dilemmas
Preliminary data from a lupus pregnancy LEGACY cohort presented at #EULAR23 are alarming.
Dr. Bella Mehta ( @bella_mehta ) shares more.
https://t.co/cY2G4s4yR0 https://t.co/isepEb8OXD
Links:
Dr. John Cush RheumNow ( View Tweet)
The future of lupus treatment is oral therapies?
There has been an explosion of trials in SLE, including nonrenal and glomerulonephritis studies.
@Janetbirdope
https://t.co/IQ9bxbTSV4 https://t.co/jVYOphxpAE
Links:
Dr. John Cush RheumNow ( View Tweet)
Wasn’t following the SLE stuff #EULAR2023 but heard a lot of talk about both telitacicept & CAR-T, including meeting highlights by Christian Dejaco.
Both look pretty exciting - the longer the sustained remission with CAR-T, the more it looks like maybe the real deal @RheumNow https://t.co/oKzb8ojTcz
David Liew drdavidliew ( View Tweet)
#EULAR2023 #POS1156 Previous case series reported ~9% de novo nephritis in #SLE pts treated with belimumab for non-renal lupus. Post-hoc analysis of 5 BEL Non-LN RCTs showed 8% had de novo LN. Risk increased in Asians but lowered with low dose BEL or s/c form @RheumNow https://t.co/GqAr3tppWh
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
New 2023 @eular_org SLE recommendations
Key changes, in response to evidence:
- more caution re: steroids
- biologics earlier
- combo therapy (BEL or CNI/VCS) considered for lupus nephritis
#EULAR2023 @RheumNow https://t.co/J3Lp8owRyT
David Liew drdavidliew ( View Tweet)
Key points from #EULAR2023 on how to manage SLE
@RheumNow https://t.co/vJy7Cg7w8N
David Liew drdavidliew ( View Tweet)
#ClinicalPearl This is cool - think of SGLT2 for #lupus #nephritis? presented at #SLE recommendations @RheumNow #EULAR2023 @eular_org https://t.co/8mbNt2n64v
Janet Pope Janetbirdope ( View Tweet)
#SLE #EULAR recommendations What is new - use LESS #glucocorticoids, aim for none or 5 mg/d or less, use #biologics early if needed to prevent damage, #lupus #nephritis consider less pulse dose if using, voclosporin vs Belimumab ? it depends @RheumNow #EULAR2023 https://t.co/Ylnnl3pHOK
Janet Pope Janetbirdope ( View Tweet)
Diagnostic delay in #lupus is really prevalent!
#EULAR2023 @RheumNow
20% with new lupus diagnosis are hospitalized!
20% diagnosis is delayed for more than 3 months! https://t.co/1vCcezBrQS
Bella Mehta bella_mehta ( View Tweet)
Meds in #lupus at #EULAR2023 recs
- HCQ first line therapy. Target dose remains the same. Some discussion on monitoring levels if possible
- MAIN CHANGE - Glucocorticoids to be minimized (only use for bridging). Nephrologists more so in favor of steroid free remission @RheumNow https://t.co/d8WnUOgrwq
Bella Mehta bella_mehta ( View Tweet)
CAR-T cells in refarctory SLE- long term data presented #EULAR2023
Pts did well except some mild cytopenias. Pts remained in remission.
Maybe a good option in the near future for refractory pts!
@RheumNow https://t.co/NWoFBipOiQ
Bella Mehta bella_mehta ( View Tweet)
With the single cell RNA sequencing analysis being my more affordable (relatively) and widely used! Science is moving forward. Highlights in basic science and translational data #EULAR2023 @RheumNow https://t.co/sS7xLeNyLW
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 #LB0005 Can we improve trial design of Bcell depletion in #SLE? Feasibility RCT of RTX in organ specific MSK showed: a)feasible to use ultrasound & clinical as endpoints, b)new tool LAMDA is responsive, c)potential worsening before later improvement with RTX @RheumNow https://t.co/kGDZ6EqLtq
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Promising new therapies in SLE
Dr. Yuz Yusof ( @Yuz6Yusof ) weighs in.
The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians.
https://t.co/0G6EMYp2mb https://t.co/Yc31sR4fRE
Links:
Dr. John Cush RheumNow ( View Tweet)
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Dr. John Cush RheumNow ( View Tweet)
#EULAR2023 #OP0290 Heterogeneity in #SLE is not only disease features but think of ANCESTRY. Data from BILAG-BR registry showed worse outcomes in people of Black and South Asian treated with either Rituximab or Belimumab (adjusted for deprivation index) @RheumNow https://t.co/bcdu9RIFSx
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Predictors of first hospitalizations due to disease activity and infections in #lupus 1341 pts from multicenter latin american cohort. 33% with atleast one hospitalization, and 3/4th due to disease activity.
@rheumnow #EULAR2023 abt#POS0169 https://t.co/vbJU4220is
Bella Mehta bella_mehta ( View Tweet)
Evaluation of diagnostic performance of ACR 1997, SLICC 2012 and EULAR /ACR diagnostic crieteria in childhood onset #SLE - SLICC highest sensitivity early in the disease,
ACR1997 has the highest specificity both at diagnosis ans over time.
@RheumNow #EULAR2023 abst#POS0136
Bella Mehta bella_mehta ( View Tweet)
